ArticleACS nano2013
A comparative study of hollow copper sulfide nanoparticles and hollow gold nanospheres on degradability and toxicity.
Article in ACS nano, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 314 citations in OpenAlex.
- Emerging Plasmonic Nanomaterials for SERS-Based Disease Diagnostics: Innovations, Clinical Challenges, and AI Integration.Molecules (Basel, Switzerland) · 2026Review
- Highly Active CuAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Elemental Composition and Degradation Rate Impact the Biocompatibility of Copper Chalcogenide Nanocrystals.ACS applied materials & interfaces · 2026Article
- Elemental Composition and Degradation Rate Impact the Biocompatibility of Copper Chalcogenide Nanocrystals.bioRxiv : the preprint server for biology · 2026Article
- Sorafenib nanomedicine in HCC: nano-bio interactions and combination therapies.Journal of nanobiotechnology · 2026Review
- Advances in Versatile Copper Sulfide-Based Nanoplatforms: From Synthesis and Properties to Multifaceted Biomedical Applications.International journal of nanomedicine · 2026Review
- Tailoring Advanced Metal-Based Nanomedicines for Adaptable Nanodynamic Disease Therapies and Theranostics.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Overcoming chemoresistance via NO-mediated HSP inhibition using hybrid membrane-coated multifunctional nanoplatforms.Materials today. Bio · 2025Article
- Recent advances in copper sulfide nanoparticles for cancer diagnosis and therapy.Materials today. Bio · 2025Review
- Bornite (CuPhotoacoustics · 2024Article
- Cuproptosis-based layer-by-layer silk fibroin nanoplatform-loaded PD-L1 siRNA combining photothermal and chemodynamic therapy against metastatic breast cancer.Materials today. Bio · 2024Article
- Au@CuS Nanoshells for Surface-Enhanced Raman Scattering Image-Guided Tumor Photothermal Therapy with Accelerated Hepatobiliary Excretion.Pharmaceutics · 2024Article
- Laser-Synthesized Germanium Nanoparticles as Biodegradable Material for Near-Infrared Photoacoustic Imaging and Cancer Phototherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- The utilization of nanotechnology in the female reproductive system and related disorders.Heliyon · 2024Review
- Nanomaterial-Enabled Photothermal Heating and Its Use for Cancer Therapy via Localized Hyperthermia.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Metallic Copper-Based Dual-Enzyme Biomimetic Nanoplatform for Mild Photothermal Enhancement of Anticancer Catalytic Activity.Biomaterials research · 2024Article
- Photothermal therapy of copper incorporated nanomaterials for biomedicine.Biomaterials research · 2023Review
- Microenvironment-responsive Cu-phenolic networks coated nanofibrous dressing with timely macrophage phenotype transition for chronic MRSA infected wound healing.Materials today. Bio · 2023Article
- In vivo synergistic tumor therapies based on copper sulfide photothermal therapeutic nanoplatforms.Exploration (Beijing, China) · 2023Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 3 countries.
Funding
Abstract
Gold and copper nanoparticles have been widely investigated for photothermal therapy of cancer. However, degradability and toxicity of these nanoparticles remain concerns. Here, we compare hollow CuS nanoparticles (HCuSNPs) with hollow gold nanospheres (HAuNS) in similar particle sizes and morphology following intravenous administration to mice. The injected pegylated HCuSNPs (PEG-HCuSNPs) are eliminated through both hepatobiliary (67 percentage of injected dose, %ID) and renal (23 %ID) excretion within one month postinjection. By contrast, 3.98 %ID of Au is excreted from liver and kidney within one month after iv injection of pegylated HAuNS (PEG-HAuNS). Comparatively, PEG-HAuNS are almost nonmetabolizable, while PEG-HCuSNPs are considered biodegradable nanoparticles. PEG-HCuSNPs do not show significant toxicity by histological or blood chemistry analysis. Principal component analysis and 2-D peak distribution plots of data from matrix-assisted laser desorption ionization-time-of-flight imaging mass spectrometry (MALDI-TOF IMS) of liver tissues demonstrated a reversible change in the proteomic profile in mice receiving PEG-HCuSNPs. This is attributed to slow dissociation of Cu ion from CuS nanoparticles along with effective Cu elimination for maintaining homeostasis. Nonetheless, an irreversible change in the proteomic profile is observed in the liver from mice receiving PEG-HAuNS by analysis of MALDI-TOF IMS data, probably due to the nonmetabolizability of Au. This finding correlates with the elevated serum lactate dehydrogenase at 3 months after PEG-HAuNS injection, indicating potential long-term toxicity. The comparative results between the two types of nanoparticles will advance the development of HCuSNPs as a new class of biodegradable inorganic nanomaterials for photothermal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.